方法：选取2013-03/2016-06在我院治疗的BRVO合并黄斑水肿患者67例67眼，将患者随机分为观察组(31例31眼)和对照组(36例36眼)，观察组采用眼底激光治疗联合雷珠单抗，对照组单纯行黄斑区格栅样光凝治疗，观察两组最佳矫正视力(BCVA)、黄斑中心凹视网膜厚度(CMT)及黄斑区渗漏情况。

结果：观察组治疗后1、2、3mo BCVA分别为0.41±0.07、0.42±0.05、0.48±0.05，明显高于对照组，差异有统计学意义(P<0.05)； 观察组治疗后1、2、3mo CMT分别为203.11±59.13、201.41±56.22、204.22±60.13μm，明显低于对照组，差异有统计学意义(P<0.05)； 观察组治疗后3mo血管渗漏明显好于对照组，差异有统计学意义(P<0.05)，其中观察组无渗漏比例为71%； 两组未观察到术后感染、无菌性眼内炎等并发症发生。

结论：雷珠单抗联合激光治疗BRVO合并黄斑水肿有较好的疗效，能改善患者视力，消除黄斑水肿，安全可靠。

METHODS: We selected 67 patients(67 eyes)with BRVO and macular edema in our hospital from March 2013 to June 2016, they were randomly divided into observation group(n=31)and control group(n=36). The observation group was treated with ranibizumab combined with laser treatment. The control group was treated with macular grid photocoagulation. We observed best corrected visual acuity(BCVA), centre macular thickness(CMT)and macular leakage of two groups.

RESULTS: The BCVA of observation group at 1, 2 and 3mo after treatment were 0.41±0.07, 0.42±0.05 and 0.48±0.05, significantly higher than those of the control group(P<0.05). The CMT of observation group at 1, 2 and 3mo after treatment were 203.11±59.13μm, 201.41±56.22μm and 204.22±60.13μm, significantly lower than those of the control group(P<0.05). The blood vessel leakage of observation group at 3mo after treatment was significantly better than that of the control group(P<0.05). No leakage ratio in the observation group was 71%. There were no postoperative infection, aseptic endophthalmitis and other complications in the two groups.

CONCLUSION: Ranibizumab combined with laser treatment in patients with BRVO and macular edema has better curative effect, can improve the visual acuity of patients, eliminate macular edema, and is safe and reliable.